XJPX
4543
Market cap21bUSD
Oct 09, Last price
2,284.00JPY
1D
-1.06%
1Q
4.34%
Jan 2017
5.86%
Name
Terumo Corp
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Terumo Corporation is a global enterprise dedicated to the development, manufacturing, and distribution of a wide array of medical products and equipment. Its comprehensive operations are structured across three primary divisions: the Cardiac and Vascular Company, the Medical Care Solutions Company, and the Blood and Cell Technologies Company. The Cardiac and Vascular Company focuses on cardiovascular and neurovascular interventions. Its product portfolio encompasses a variety of devices, including angiographic guidewires, catheters, introducer sheaths, vascular closure devices, PTCA balloon catheters, coronary stents, and self-expanding peripheral stents, alongside advanced intravascular ultrasound systems and imaging catheters. This division also develops specialized devices for treating cerebral aneurysms, such as coils, stents, and intrasaccular devices, as well as embolization systems, aspiration catheters, and clot retrievers for ischemic stroke. Furthermore, it supplies critical components for cardiac surgery, including oxygenators and cardio-pulmonary bypass systems, in addition to artificial vascular and stent grafts. The Medical Care Solutions Company addresses a broad spectrum of general medical and patient care needs. Offerings include essential medical supplies like syringes, infusion and syringe pumps, infusion lines, I.V. solutions, peritoneal dialysis fluids, and products for pain management and nutritional support, as well as adhesion barriers. This segment also produces consumer health monitoring devices such as blood glucose monitoring systems, disposable needles for pen-injectors, insulin patch pumps, blood pressure monitors, and digital thermometers. Moreover, it provides contract manufacturing services for pharmaceutical companies, specializing in prefilled syringes and devices like prefillable syringes and needles for pharmaceutical packaging. Finally, the Blood and Cell Technologies Company concentrates on products and systems for blood and cell management. Its offerings span blood bags, component collection systems, automated blood processing systems, pathogen reduction systems, centrifugal apheresis systems, and advanced cell expansion systems. Established in 1921, the company was initially known as Sekisen Ken-onki Corporation before adopting its current name, Terumo Corporation, in October 1974. Terumo Corporation maintains its corporate headquarters in Tokyo, Japan.
Related entities
Subsidiaries (3)
Terumo BCT Europe
TERUMO EUROPE
VASCUTEK LIMITED
Key people
Miho Mizuguchi
Executive Officer, Chief Legal Officer(CLO), Manager of CLO Office · since 2023
Toshio Nakashima
Executive Officer, Manager of Aitaka Plant in Cardiac and Vascular Company, Deputy Chief Operations Officer (COO) of TIS Business in Cardiac and Vascular Company · since 2022
Cindy Ng
Group Executive Officer, Senior Vice Presidentof Global Commercial of Blood and Cell Technologies Company · since 2025
Shinji Omori
Chief Technology Officer, Executive Officer, Manager of R&D Center · since 2025
Erik Pomp
Executive Officer, President of the Vascular Business in Cardiac and Vascular Company, CEO of Terumo Aortic · since 2022
James Rushworth
Executive Officer, Chief Commercial Officer (CCO) of TIS Business in Cardiac & Vascular Company, President & Chief Executive Officer of Subsidiary · since 2022
Sakae Sasaki
Executive Officer · since 2025
Carsten Schroeder
Executive Officer, President of Neurovascular Business in Cardiovascular Company, CEO of Subsidiary · since 2022
Takumi Uchida
Executive Officer, Chief Operations Officer (COO) of Medical Care Solutions Company · since 2024
Chris Williams
Group Executive Officer, Senior Vice President of Global Manufacturing in Blood and Cell Technologies Company · since 2024
Jun Yamashita
Executive Officer, Chief Quality Officer · since 2024
Masanobu Yano
Group Executive Officer · since 2025
Hikaru Samejima
President, Chief Executive Officer, Representative Director · since 2024
Takanori Shibazaki
Director · since 2021
Toshiaki Takagi
Chairman of the Board, Representative Director · since 2022
Mari Kogiso
Independent Director · since 2024
Hidenori Nishi
Independent Director · since 2020
Keiya Ozawa
Independent Director · since 2021
Soichiro Uno
Independent Director · since 2019
Headquarters & legal address
幡ヶ谷二丁目44番1号
東京都 渋谷区 151-0072
JP
東京都 渋谷区 151-0072
JP
Address
2-44-1, Hatagaya
Shibuya-ku Tokyo 151-0072
JP
Shibuya-ku Tokyo 151-0072
JP
Other language
Terumo Corporation
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||